Manufactures and sells pharmaceutical active ingredients, with a focus on pain management APIs. Runs contract development and manufacturing projects for global innovator drug companies, with 3 molecules currently under development for 2 such companies, and has filed 21 Drug Master Files to date. In Q1 FY27, acquired a 63.98% stake in Remember India Health Links to enter finished dosage formulations, bringing in 30+ formulation dossiers, and incorporated two new subsidiaries to build a presence in peptides/biosimilars and surgical implants/medical devices. Sells to pharmaceutical, nutraceutical, veterinary and personal care customers across 15+ countries and has begun diversifying into industrial and fine chemicals. Raw materials form the bulk of operating costs, with depreciation and employee costs making up smaller shares. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Active Pharmaceutical Ingredients (APIs), CDMO services, Finished Dosage Formulations, Industrial & Fine Chemicals. Pharmaceutical API manufacturer and CDMO player diversifying into formulations, biologics and medical devices.
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 172 |
| EBITDA (ex other income) | 48 |
| margin % | 27.6 |
| Owners' profit | 29 |
| EPS, as reported (₹) | 6.11 |
| ROE % · ROCE % | 11.4 · 17.4 |
| Debt / equity (x) | 0.17 |
| Cash from operations | (79) |
| Capex | 0 |
| ₹ crore | Q4 FY26 | Q1 FY27 |
|---|---|---|
| Revenue | 51 | 88 |
| Profit before tax | 14 | 14 |
| Net profit | 11 | 8 |
| EPS (₹) | 2.33 | 0.16 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 7 Sept 2026 · Revised AGM Proceedings Filed; 8.59 Crore Preferential Share Issuance Tabled | board shareholder meetings | low | — | — |
| 5 Sept 2026 · AGM results: All 11 resolutions passed, including 8.59 crore preferential share issuance | board shareholder meetings | low | — | — |
| 5 Sept 2026 · Anlon Healthcare 13th AGM held; major preferential share issue on agenda | board shareholder meetings | low | — | — |
| 25 Aug 2026 · Corrigendum to Anlon Healthcare AGM notice on preferential issue | board shareholder meetings | low | — | — |
| 17 Aug 2026 · Anlon Healthcare publishes newspaper notice for 13th AGM on Sept 5 | compliance | minimal | — | — |
| 13 Aug 2026 · Board okays share swap deals for AOPL and BLPL stakes; AGM on Sept 5 | board shareholder meetings | low | — | — |
| 13 Aug 2026 · Board approves share swap to acquire AOPL and BLPL stakes, raises capital | board shareholder meetings | low | — | — |
| 13 Aug 2026 · Anlon revises acquisition stakes in Apiqo Organics and Bizotic Lifescience via share swap | general | low | — | — |
| 12 Aug 2026 · Anlon Q1 FY27 transcript: revenue up, margin dip, FY27 guide 380-400 cr | investor communications | medium | — | — |
| 11 Aug 2026 · Board Meeting postponed to August 13, 2026 due to admin reasons | board shareholder meetings | low | — | — |
| Where a broker report shows | This document shows |
|---|
| 96,656 |
| 26.3 |
| 2.55 |
| 13.4 |
| 9.2 |
| 12.6 |
| 6.3 |
| 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 7.9 | 28.9 | 19 of 169 | 89% |
| P/B | 4.1 | 3.3 | 98 of 163 | 40% |
| ROCE | 16.0 | 10.8 | 54 of 183 | 71% |
| ROE | 11.4 | 10.4 | 77 of 171 | 55% |
| Debt / Equity | 0.2 | 0.1 | 93 of 171 | 46% |
| EBITDA margin | 17.9 | 17.5 | 80 of 165 | 52% |
| Market cap | 1045 | 839 | 88 of 182 | 52% |
| Why |
|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
